Bausch Health Cos Financial Activities - Other 2010-2025 | BHC

Bausch Health Cos financial activities - other from 2010 to 2025. Financial activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the financing activities section of the Cash Flows Statement.
Bausch Health Cos Annual Financial Activities - Other
(Millions of US $)
2024 $-69
2023 $-106
2022 $-139
2021 $-173
2020 $-107
2019 $-111
2018 $-193
2017 $-177
2016 $-780
2015 $-406
2014 $-210
2013 $-246
2012 $-160
2011 $-225
2010 $-56
2009 $-27
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.692B $9.625B
Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.207B 6.94
Dr Reddy's Laboratories (RDY) India $12.054B 21.88
BridgeBio Pharma (BBIO) United States $6.426B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.872B 15.19
Amphastar Pharmaceuticals (AMPH) United States $1.181B 7.87
Taysha Gene Therapies (TSHA) United States $0.580B 0.00
Personalis (PSNL) United States $0.437B 0.00
Assembly Biosciences (ASMB) United States $0.103B 0.00
Sol-Gel Technologies (SLGL) Israel $0.021B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00